Healthcare
Cambridge Cognition Holdings Plc(COG)
Live Price
Offline$35.00
+0.00% today
1Y Change
+4.48%
Window
Jun 25, 2025 โ Jun 19, 2026
- Market Cap
- $27.06B
- Revenue Growth
- +55.4%
- EPS Growth
- +49.0%
- Dividend Yield
- 2.5%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cambridge Cognition Holdings Plc (COG) is a Healthcare stock with a market cap of $27.06B and listed on LSE. The stock last traded around $35.00 and up 4.5% across the available one-year price window (Jun 25, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of +55.4%, EPS growth of +49.0%, a dividend yield of 2.5%. What stands out right now is revenue +55.4%, EPS +49.0%, free cash flow +43.9% with operating margin 29.4% and ROIC 7.1%. The dividend is present but secondary, with a yield around 2.5%. Valuation is more restrained than many high-expectation growth names at P/E 15.8 and price/sales 3.7. Stock Foundry combines COG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+55.4% vs +7.6% peer median
Operating Margin
Above sector median
+29.4% vs +19.4% peer median
P/E
Below sector median
15.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2021 was reported on Oct 27, 2021, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +55.4% and EPS at +49.0%, with operating margin around 29.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2021 Oct 27, 2021 | โ | +0.0% | -4.5% | -3.0% |
2021 Jul 30, 2021 | -7.1% | +0.0% | -4.5% | -3.0% |
2021 Apr 29, 2021 | +5.6% | +0.0% | -4.5% | -3.0% |
Benchmark Edge
COG vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COG
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COG Max Drawdown
-31.25%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COG and SPY.
Company Overview
Cambridge Cognition Holdings Plc
LSE
Cambridge Cognition Holdings Plc is a technology company specializing in the development and commercialization of digital solutions for cognitive assessment. Their primary function is to offer software products that enable the precise measurement of brain function, which are used extensively in clinical trials, academic research, and healthcare settings. Notable for its impact on the pharmaceutical and healthcare industries, this company provides technologies that support the diagnosis, monitoring, and treatment of mental health conditions. Its digital health solutions cater to a wide range of cognitive functions, including memory, attention, and executive functions, underpinning advances in neurology and psychology. Cambridge Cognition Holdings Plc plays a significant role in the market by facilitating drug development processes and enabling healthcare providers to enhance patient outcomes. Headquartered in the UK, the company is recognized for its contributions to advancing mental health diagnostics and treatments in collaboration with leading universities and global healthcare organizations.
- Leadership
- Mr. Robert Baker
- Employees
- 84
- Street Address
- Tunbridge Court, Tunbridge Lane Bottisham
- Mailing
- Cambridge, CB25 9TU
- Region
- Cambridge, United Kingdom
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 15.8
- EV/EBITDA
- 6.4
- Price/Sales
- 3.7
- Price/Book
- 1.8
Growth
- Revenue
- +55.4%
- EPS
- +49.0%
- Free Cash Flow
- +43.9%
Profitability
- Gross Margin
- 36.2%
- Operating Margin
- 29.4%
- Net Margin
- 23.3%
- ROE
- 11.8%
- ROIC
- 7.1%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 1.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.